RE:RE:RE:RE:RE:RE:RE:RE:What did we learn here?I don't believe so. But who knows how far this type of computerized trading has advanced by this point. AI is doing some pretty impressive, and sometimes scary, things these days. But to me, this article is a very nice addition to the pool of info regarding TH-1902 but nothing that should move the stock much more than it has, if that, as it is very early research. But it holds considerable promise for future developments. Do you know of any other drug that has had an impact on cancer stem cells?
Also, it seems like the part of TH-1902 that is attracted to the Sortilin receptor is having far more of an impact than any of us would have ever thought. We would have been content for it to get the docetaxel to the right place and let it do its thing. Instead, it seems to be having a variety of benefits besides that, which makes it fun to think about what might come next.
qwerty22 wrote: I noticed at the bottom of the page there's article metrics showing daily number of abstract views. So far 81 today. It'll be interesting to see how many view by the end of the day. Do algos read abstracts?